Hyaluronidase allergy: a rare cause of periorbital inflammation.

Australas J Dermatol

Occupational Dermatology Research and Education Centre, Skin and Cancer Foundation, 47 Hawthorn St, Coburg, Carlton, Australia.

Published: February 2010

Hyaluronidase is a bovine or ovine testicular protein that is used as an adjunct to co-administered medicaments and fluids to enhance their dispersion and absorption through the degradation of hyaluronan. While it is a known potential allergen, there are few reports of hyaluronidase hypersensitivity. A 56-year-old lady presented 8 hours post glaucoma surgery with ipsilateral lacriminorrhoea, periorbital erythema, oedema, proptosis, pruritus and conjunctival chemosis. Right ocular motility was restricted and visual acuity was reduced. The reaction settled with oral corticosteroids and antihistamines. Hyaluronidase allergy was confirmed on skin prick testing. Hyaluronidase allergy is rare. In the few cases reported, reactions occurred at various doses and were acute (intraoperative), early (within hours), intermediate (within days) or delayed (within weeks). Anaphylaxis has also been described. Primary sensitization appears to be a prerequisite for most reactions. The variability in onset of symptoms and the response to skin testing would suggest that type I and type IV hypersensitivity may both contribute to this response. In this case, the timing fitted with a late phase type 1 reaction. This case shows that despite being less common than haemorrhage for acute reactions and infection for delayed reactions, allergy can account for orbital inflammation following ophthalmic surgery.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1440-0960.2009.00593.xDOI Listing

Publication Analysis

Top Keywords

hyaluronidase allergy
12
allergy rare
8
hyaluronidase
5
rare periorbital
4
periorbital inflammation
4
inflammation hyaluronidase
4
hyaluronidase bovine
4
bovine ovine
4
ovine testicular
4
testicular protein
4

Similar Publications

Comparative Assessment of the Allergenicity of Hyaluronidases from (Pol d 2), (Ves v 2), and Venom (Api m 2).

Toxins (Basel)

November 2024

Center of Allergy and Environment (ZAUM), Technical University of Munich, School of Medicine and Health & Helmholtz Munich, German Research Center for Environmental Health, 85764 Munich, Germany.

Article Synopsis
  • * Key allergens evaluated include hyaluronidases from honey bee (Api m 2), European paper wasp (Pol d 2), and yellow jackets (Ves v 2.0101 and Ves v 2.0201), with sensitization rates among patients varying significantly.
  • * Results show that individuals primarily sensitized to Api m 2 have minimal cross-reactivity with other venoms, while those sensitized to other allergens may react to Api m 2, emphasizing the importance of identifying the primary allergen for effective
View Article and Find Full Text PDF
Article Synopsis
  • The popularity of minimally invasive cosmetic treatments, especially lip augmentation, has surged in recent years, with dermatologists providing safe and evidence-based options.
  • Various lip fillers are available and have been extensively studied for safety; however, there's limited data on their effects in patients with autoimmune diseases.
  • A specific case of a granulomatous delayed hypersensitivity reaction to hyaluronic acid filler in a patient with ankylosing spondylitis was successfully treated with hyaluronidase, emphasizing the need for awareness of such reactions and effective treatment options.
View Article and Find Full Text PDF

We previously demonstrated that the lungs of deceased COVID-19 patients were filled with a clear hydrogel consisting of hyaluronan (HA). In this translational study, we investigated the role of HA at all stages of COVID-19 disease to map the consequences of elevated HA on morbidity and identify the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced HA production. A reduced alveolar surface area was observed in the lungs of deceased COVID-19 patients compared to healthy controls, as visualized by a 3D rendering of lung morphology using light-sheet fluorescence microscopy.

View Article and Find Full Text PDF

Background: The safety, tolerability, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% (dual-vial unit of human immunoglobulin 10% and recombinant human hyaluronidase [rHuPH20]) were assessed in children with primary immunodeficiency diseases (PIDs).

Methods: This phase 4, post-authorization, prospective, interventional, multicenter study (NCT03116347) conducted in the European Economic Area, enrolled patients aged 2 to < 18 years with a documented PID diagnosis who had received immunoglobulin therapy for ≥ 3 months before enrollment. New fSCIG 10% starters underwent fSCIG 10% dose ramp-up for ≤ 6 weeks (epoch 1) before receiving fSCIG 10% for ≤ 3 years (epoch 2); patients pretreated with fSCIG 10% entered epoch 2 directly.

View Article and Find Full Text PDF

Facilitated subcutaneous immunoglobulin (fSCIG) 10% is an immunoglobulin replacement therapy that utilizes recombinant human hyaluronidase (rHuPH20) to enhance immunoglobulin dispersion and absorption, allowing for longer treatment intervals similar to intravenous immunoglobulin (up to once monthly). fSCIG 10% is indicated in the USA for treating adults and children aged ≥ 2 years with primary immunodeficiency diseases (PIDs). This prospective, non-interventional, open-label, multicenter, post-authorization safety study (NCT02593188) was conducted in the USA from November 2015 to October 2021 to assess the long-term safety of fSCIG 10% in routine clinical practice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!